{"filing":{"accession_number":"0001193125-26-324101","cik":"0001958086","ticker":"CLB","company_name":"Core Laboratories Inc. /DE/","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"clb-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1958086/000119312526324101/clb-20260729.htm"},"events":[{"id":21738,"run_id":19609,"accession_number":"0001193125-26-324101","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Core Laboratories issued a press release on July 29, 2026, announcing its second quarter 2026 financial results, including revenue of $124.6 million, operating income of $9.2 million, and EPS of $0.13, along with detailed segment performance, cash flow metrics, and Q3 2026 guidance.","company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21444,"accession_number":"0001193125-26-324101","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Core Laboratories issued a press release on July 29, 2026, announcing its second quarter 2026 financial results, including revenue of $124.6 million, operating income of $9.2 million, and EPS of $0.13. The disclosure includes detailed segment performance, cash flow metrics, guidance for Q3 2026, and management commentary on business conditions. This is a standard quarterly earnings release material to investors' assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:10:47.400553+00:00","company_name":"","ticker":null,"filing_date":""},{"id":21445,"accession_number":"0001193125-26-324101","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure contains a press release announcing Core Laboratories' second quarter 2026 financial results, including revenue of $124.6 million, operating income of $9.2 million, and EPS of $0.13. While the Item also mentions a quarterly dividend announcement ($0.01 per share), the substantive content and primary focus of the press release is the quarterly earnings disclosure with detailed segment performance, cash flow analysis, and forward guidance. This is a material earnings release that would affect a reasonable investor's assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:10:47.400553+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21444,"accession_number":"0001193125-26-324101","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Core Laboratories issued a press release on July 29, 2026, announcing its second quarter 2026 financial results, including revenue of $124.6 million, operating income of $9.2 million, and EPS of $0.13. The disclosure includes detailed segment performance, cash flow metrics, guidance for Q3 2026, and management commentary on business conditions. This is a standard quarterly earnings release material to investors' assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:10:47.400553+00:00","company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","filing_date":"2026-07-29"},{"id":21445,"accession_number":"0001193125-26-324101","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure contains a press release announcing Core Laboratories' second quarter 2026 financial results, including revenue of $124.6 million, operating income of $9.2 million, and EPS of $0.13. While the Item also mentions a quarterly dividend announcement ($0.01 per share), the substantive content and primary focus of the press release is the quarterly earnings disclosure with detailed segment performance, cash flow analysis, and forward guidance. This is a material earnings release that would affect a reasonable investor's assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:10:47.400553+00:00","company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","filing_date":"2026-07-29"}]}